MXPA04009363A - Terapia de combinacion usando peptidos trifolios. - Google Patents
Terapia de combinacion usando peptidos trifolios.Info
- Publication number
- MXPA04009363A MXPA04009363A MXPA04009363A MXPA04009363A MXPA04009363A MX PA04009363 A MXPA04009363 A MX PA04009363A MX PA04009363 A MXPA04009363 A MX PA04009363A MX PA04009363 A MXPA04009363 A MX PA04009363A MX PA04009363 A MXPA04009363 A MX PA04009363A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- trifolium
- composition
- trefoil
- chemotherapeutic
- Prior art date
Links
- 108010007389 Trefoil Factors Proteins 0.000 title claims abstract description 32
- 102000007641 Trefoil Factors Human genes 0.000 title claims abstract description 32
- 238000002648 combination therapy Methods 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 22
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 19
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 17
- 108010088411 Trefoil Factor-2 Proteins 0.000 claims abstract description 9
- 102100039172 Trefoil factor 2 Human genes 0.000 claims abstract description 9
- 108010013137 spasmolytic polypeptide Proteins 0.000 claims abstract description 8
- 230000009841 epithelial lesion Effects 0.000 claims abstract description 7
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims abstract description 5
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims abstract description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 4
- 230000003902 lesion Effects 0.000 claims abstract description 3
- 230000000202 analgesic effect Effects 0.000 claims abstract 2
- 241000219793 Trifolium Species 0.000 claims description 30
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 24
- 230000002411 adverse Effects 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 6
- 201000010927 Mucositis Diseases 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229960003685 imatinib mesylate Drugs 0.000 claims description 5
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000001297 phlebitis Diseases 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 208000004232 Enteritis Diseases 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229960002092 busulfan Drugs 0.000 claims description 3
- 229960004117 capecitabine Drugs 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 abstract description 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 abstract description 2
- 102000014456 Trefoil Factor-3 Human genes 0.000 abstract description 2
- 235000015724 Trifolium pratense Nutrition 0.000 abstract description 2
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 20
- 150000001413 amino acids Chemical group 0.000 description 14
- 238000002512 chemotherapy Methods 0.000 description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940034982 antineoplastic agent Drugs 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 230000000118 anti-neoplastic effect Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 101000889450 Homo sapiens Trefoil factor 2 Proteins 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 101000889443 Homo sapiens Trefoil factor 1 Proteins 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101100481012 Homo sapiens TFF3 gene Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 102100039175 Trefoil factor 1 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000007391 self-medication Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101000889485 Homo sapiens Trefoil factor 3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 102000051048 human TFF1 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004678 mucosal integrity Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36757402P | 2002-03-26 | 2002-03-26 | |
| US42270802P | 2002-10-31 | 2002-10-31 | |
| PCT/US2003/009195 WO2003082196A2 (en) | 2002-03-26 | 2003-03-26 | Combination therapy using trefoil peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04009363A true MXPA04009363A (es) | 2005-01-25 |
Family
ID=28678188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04009363A MXPA04009363A (es) | 2002-03-26 | 2003-03-26 | Terapia de combinacion usando peptidos trifolios. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030186880A1 (https=) |
| EP (1) | EP1494530A4 (https=) |
| JP (1) | JP2005527547A (https=) |
| CN (1) | CN1655675A (https=) |
| AU (1) | AU2003224773B2 (https=) |
| CA (1) | CA2480372A1 (https=) |
| MX (1) | MXPA04009363A (https=) |
| WO (1) | WO2003082196A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US20040171544A1 (en) * | 2001-04-24 | 2004-09-02 | Barker Nicholas P. | Trefoil domain-containing polypeptides and uses thereof |
| US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US7538082B2 (en) | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| US20060189526A1 (en) * | 2002-04-24 | 2006-08-24 | Podolsky Daniel K | Compositions containing an intestinal trefoil peptide and a mucoadhesive |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
| WO2003030824A2 (en) * | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
| US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
| AU2003286844A1 (en) * | 2002-10-31 | 2004-05-25 | The General Hospital Corporation | Trefoil domain-containing polypeptides and uses thereof |
| US8075771B2 (en) * | 2005-02-17 | 2011-12-13 | E. I. Du Pont De Nemours And Company | Apparatus for magnetic field gradient enhanced centrifugation |
| CN100381560C (zh) * | 2005-09-27 | 2008-04-16 | 中国人民解放军第三军医大学第一附属医院 | 采用gs115酵母菌合成重组人肠三叶因子的工艺 |
| WO2013176785A1 (en) | 2012-05-21 | 2013-11-28 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor and uses thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US11090358B2 (en) | 2015-09-09 | 2021-08-17 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| US20190375786A1 (en) | 2016-09-09 | 2019-12-12 | Fred Hutchinson Cancer Research Center | Stable peptides and methods of use thereof |
| AU2018210157B2 (en) | 2017-01-18 | 2022-10-06 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| AU2018283161A1 (en) | 2017-06-15 | 2020-01-02 | Blaze Bioscience, Inc. | Renal-homing peptide conjugates and methods of use thereof |
| EP3727146A4 (en) | 2017-12-19 | 2021-10-06 | Blaze Bioscience, Inc. | TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE |
| US20230173028A1 (en) * | 2020-03-30 | 2023-06-08 | Shandong Ruiying Pioneer Pharmaceutical Co., Ltd | Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US151472A (en) * | 1874-06-02 | Improvement in rotary engines | ||
| US4370317A (en) * | 1980-09-10 | 1983-01-25 | Novo Industri A/S | Pancreatic spasmolytic polypeptide |
| US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US6221840B1 (en) * | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6063755A (en) * | 1991-02-14 | 2000-05-16 | The General Hospital Corporation | Intestinal trefoil proteins |
| US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
| DK6893D0 (da) * | 1993-01-21 | 1993-01-21 | Novo Nordisk As | Peptid |
| US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| CN1070867C (zh) * | 1994-08-26 | 2001-09-12 | 诺沃挪第克公司 | 三叶形肽双体 |
| US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US20030078205A1 (en) * | 2001-07-31 | 2003-04-24 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US6426404B1 (en) * | 1997-08-25 | 2002-07-30 | The General Hospital Corporation | Receptor for intestinal trefoil factor |
| JP2002523452A (ja) * | 1998-08-26 | 2002-07-30 | スミスクライン・ビーチャム・コーポレイション | 肺疾患の治療方法 |
| US6372439B2 (en) * | 1998-10-01 | 2002-04-16 | James R. Goldenring | Screen for gastric adenocarcinoma |
| PT1194554E (pt) * | 1999-07-05 | 2007-01-31 | Vlaams Interuniv Inst Biotech | Libertação de péptidos trifólios |
| WO2001041779A2 (en) * | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
| AU2590201A (en) * | 1999-12-23 | 2001-07-03 | Human Genome Sciences, Inc. | Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| MXPA03004546A (es) * | 2000-11-22 | 2003-09-10 | Rxkinetix Inc | Tratamiento de mucositis. |
| CA2444885A1 (en) * | 2001-04-24 | 2002-10-31 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US7538082B2 (en) * | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| JP2004534801A (ja) * | 2001-06-14 | 2004-11-18 | ノボ ノルディスク アクティーゼルスカブ | Ｔｆｆ２ペプチドによる粘膜修復 |
| US20030153496A1 (en) * | 2001-06-14 | 2003-08-14 | Lars Thim | Mucosal repair by TFF dimer peptides |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| WO2003030824A2 (en) * | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
| US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
| JP2005532988A (ja) * | 2001-11-28 | 2005-11-04 | ザ ジェネラル ホスピタル コーポレーション | 呼吸上皮の病変を治療するための方法および組成物 |
| US20030215431A1 (en) * | 2002-02-11 | 2003-11-20 | Lars Thim | Management of mucosal viscosity by TFF monomer peptides |
| US6780383B1 (en) * | 2003-02-28 | 2004-08-24 | Eugene Ettlinger | System for sterilization of spaces and surfaces |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| EP1893953A2 (en) * | 2005-05-18 | 2008-03-05 | The GI Company, Inc | Oral drug delivery system and methods of use thereof |
| CN101501057A (zh) * | 2005-07-25 | 2009-08-05 | Gi公司 | 用于生产itf的酵母表达载体 |
-
2003
- 2003-03-26 CN CNA038120402A patent/CN1655675A/zh active Pending
- 2003-03-26 MX MXPA04009363A patent/MXPA04009363A/es unknown
- 2003-03-26 US US10/397,953 patent/US20030186880A1/en not_active Abandoned
- 2003-03-26 WO PCT/US2003/009195 patent/WO2003082196A2/en not_active Ceased
- 2003-03-26 CA CA002480372A patent/CA2480372A1/en not_active Abandoned
- 2003-03-26 JP JP2003579739A patent/JP2005527547A/ja active Pending
- 2003-03-26 EP EP03721462A patent/EP1494530A4/en not_active Withdrawn
- 2003-03-26 AU AU2003224773A patent/AU2003224773B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005527547A (ja) | 2005-09-15 |
| AU2003224773B2 (en) | 2010-08-26 |
| EP1494530A2 (en) | 2005-01-12 |
| US20030186880A1 (en) | 2003-10-02 |
| WO2003082196A3 (en) | 2003-12-04 |
| WO2003082196A2 (en) | 2003-10-09 |
| CN1655675A (zh) | 2005-08-17 |
| EP1494530A4 (en) | 2009-06-24 |
| CA2480372A1 (en) | 2003-10-09 |
| AU2003224773A1 (en) | 2003-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04009363A (es) | Terapia de combinacion usando peptidos trifolios. | |
| EP2992008B1 (en) | Therapeutic peptides | |
| US9730984B2 (en) | Composition for preventing or treating rheumatoid arthritis | |
| JP6552117B2 (ja) | 敗血症の予防治療剤 | |
| AU2011331901B2 (en) | Anti-inflammatory compositions | |
| US20100144618A1 (en) | Compositions containing an intestinal trefoil peptide and a mucoadhesive | |
| CN102026641A (zh) | 并用或组合dpp-iv抑制剂和其它糖尿病治疗药的药品 | |
| KR20110092351A (ko) | 방사선 및 화학요법 손상에서 사용되는 국소적 활성 스테로이드 | |
| WO2003103697A2 (en) | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity | |
| US20030181383A1 (en) | Methods and compositions for treating oral and esophageal lesions | |
| US9295669B2 (en) | Combination therapy for proliferative disorders | |
| CN107629114A (zh) | 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用 | |
| AU2024246525A1 (en) | Methods and uses for treating nausea and emesis | |
| CN115947821B (zh) | 一种glp-1类似物 | |
| HK1116691A (en) | Combination therapy using trefoil peptides | |
| Zhu et al. | Intracellular calcium channels: Potential targets for type 2 diabetes mellitus? | |
| EP3421484A1 (en) | Polypeptide, derivatives thereof, and application thereof in preparation of drugs having resistance to pulmonary fibrosis | |
| KR20240108437A (ko) | 면역성 혈소판 감소증 치료에 있어서 퀴놀리논 유도체의 용도 | |
| CN101152563A (zh) | 利用三叶肽的联合治疗 | |
| CN120939206A (zh) | Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用 | |
| CN115364195A (zh) | Thiostrepton在制备预防和治疗硬皮病的药物中的应用 | |
| CN108853483B (zh) | 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途 | |
| TW202606654A (zh) | 用於預防及治療肥胖及相關病狀及病症之方法 | |
| HK1081401A (en) | Combination therapy using trefoil peptides | |
| ZA200307901B (en) | Use of the protein UK114 or of fragments thereof for the treatment and prevention of the endotoxic shock. |